A sequential pharmacokinetic (PK) and pharmacodynamic (PD) model was built with
Nonlinear Mixed Effects Modelling based on data from a first-in-human trial of a novel biologic,
MEDI7836. MEDI7836 is a human immunoglobulin G1 lambda (IgG1λ-YTE) monoclonal antibody,
with an Fc modification to reduce metabolic clearance. MEDI7836 specifically binds to, and functionally
neutralizes interleukin-13. Thirty-two healthy male adults were enrolled into a dose-escalation
clinical trial. Four active doses were tested (30, 105, 300, and 600 mg) with 6 volunteers enrolled
� Copyright©2013. Inventi Journals Pvt.Ltd. All Right Reserved.